How a second macrocycle turned a 2.5-fold starting point into RMC-0708 — an orally bioavailable, >200-fold KRAS Q61H-selective RAS(ON) tri-complex inhibitor, with the deposited co-crystal to prove it.
Read article →
A structure-guided, brain-penetrant covalent BChE inhibitor for late-stage Alzheimer's: (S)-(+)-14 carbamoylates the catalytic Ser198 (hBChE IC50 30 nM, no AChE activity), is CNS+, and reverses scopolamine-induced cognitive deficits in mice with no cholinergic side effects — with a co-crystal to prove the mechanism.
Read article →
A clever twist on sirtuin inhibition: acyl-lysine peptides branched at the reacting carbon dock perfectly on NAD+ but refuse to turn over. The lead (KK3) hits SIRT2 at 5 nM in vitro / 13 nM in cells, with no covalent intermediate — validated by 1.8 Å ternary co-crystals.
Read article →
Stanford's next-generation ALDH1B1 inhibitor swaps a metabolically labile biaryl for an aryl-cyclohexyl ether bioisostere: IC50 ~10 nM, 10-fold selectivity for 3D colorectal and pancreatic cancer cultures, and markedly better metabolic stability.
Read article →
Macrocyclizing flexible bosutinib locks its 3-cyanoquinoline into AZ137 (HIPK4 IC50 11 nM) — a first-in-class selective chemical probe for a dark kinase, delivered without a target crystal structure. With a redrawn macrocyclization route and a CLK3-surrogate binding render.
Read article →